About Emtherapro
Emtherapro is a Healthcare company based in Decatur (United States) founded in 2021 by Nicholas Seyfried, Allan Levey, and Duc Duong. Drug discovery, biomarker identification, validation, and clinical trials are provided. Emtherapro has raised $3 million across 1 funding round. Its chief executive, as recorded, is Kiran Pandey. Emtherapro offers products and services including Precision Medicine Platform and AI Analytics Service. Its focus areas include Biopharma Outsourcing, Diversified and Small Molecules & Peptides. Its competitors include Pfizer, LabConnect and Ainos; 2 of its 3 listed competitors have raised funding.
Company details
Emtherapro was founded in 2021 in Decatur, United States, as a contract research organization in the biotechnology and pharmaceutical sectors. Services encompass drug discovery, biomarker identification and validation, and clinical trials support. Operations are centered on these core areas to assist pharmaceutical development. Leadership includes co-founders Nicholas Seyfried as CSO, Allan Levey as President, and Duc Duong as COO, with Kiran Pandey serving as CEO.
- Headquarters Decatur, United States
- Founders Nicholas Seyfried, Allan Levey, Duc Duong
- SectorsHealthcare
- Website emtherapro.com
- Total Equity Funding$3M (USD)
in 1 rounds
- Latest Funding Round$3M (USD), Seed
Sep 2023
Products & Services of Emtherapro
Emtherapro offers a comprehensive portfolio of products and services, including Precision Medicine Platform and AI Analytics Service.
Enables data generation and insights for developing therapies in neurodegenerative diseases
Uses machine learning for deriving actionable insights in drug discovery and trials
Funding Insights of Emtherapro
Emtherapro has successfully raised a total of $3M through 1 strategic funding round. The most recent funding activity was a Seed round of $3 million completed in September 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $3M
- Total Rounds 1
- Last Round Seed — $3M
- First Round $3M
(Sep 2023)
All 1 funding rounds of Emtherapro with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2023 | $3M | Seed | – | – | – |
People of Emtherapro
4 people are tracked at Emtherapro (4 in leadership).
| Name | Role | Group |
|---|---|---|
Nicholas Seyfried | Co-Founder & CSO | Leadership |
Allan Levey | Co-Founder & President | Leadership |
Duc Duong | Co-Founder & COO | Leadership |
Kiran Pandey | CEO | Leadership |
Complete people profiles for Emtherapro
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Emtherapro
2 dated milestones of Emtherapro across 2 years, from founding to its latest funding, stage changes and deals.
- Founded Emtherapro is founded.
- Funding First funding round of $3.0M.
Competitors of Emtherapro
Emtherapro has 3 listed competitors in our database, 2 of them funded. They include Pfizer, LabConnect and Ainos.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| pfizer.com | 1849 | New York, United States | $8M | Pharmaceutical products for treating multiple diseases are provided. | ||
| labconnect.com | 2002 | Johnson, United States | $28.5M | Laboratory testing, clinical trial research, and biopharma services are provided. | ||
| ainos.com | 1986 | San Diego, United States | 43 | Novel point-of-care testing and low-dose interferon therapeutics are developed. |
Detailed competitors of Emtherapro
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Biopharma Outsourcing & Drug Delivery
3 companies that operate in the same segment as Emtherapro (Biopharma Outsourcing & Drug Delivery) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Suite solutions are provided for payers and healthcare providers. | 1998 | Princeton, New Jersey, United States | USD 220 M | USD 374.1 M | 4,490 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Emtherapro
Emtherapro was founded in 2021 and raised its 1st funding round 2 years after it was founded.
Emtherapro is headquartered in Decatur, United States.
Kiran Pandey is the CEO of Emtherapro, as recorded in our data.
Emtherapro is a funded company, having raised a total of $3M across 1 funding round to date. The company's 1st funding round was a Seed of $3M, raised on Sep 2023.
Emtherapro was founded in 2021 in Decatur, United States, as a contract research organization in the biotechnology and pharmaceutical sectors. Services encompass drug discovery, biomarker identification and validation, and clinical trials support. Operations are centered on these core areas to assist pharmaceutical development. Leadership includes co-founders Nicholas Seyfried as CSO, Allan Levey as President, and Duc Duong as COO, with Kiran Pandey serving as CEO.
Emtherapro's top competitors include Pfizer, LabConnect and Ainos.
Emtherapro offers Precision Medicine Platform and AI Analytics Service.